Literature DB >> 2421884

Characterization and modulation of human lymphokine (interleukin 2) activated killer cell induction.

M Hoyer, T Meineke, W Lewis, B Zwilling, J Rinehart.   

Abstract

Culture of human peripheral blood mononuclear cells with purified interleukin 2 (IL-2) results in the induction of a cytotoxic population of cells capable of lysing autologous tumor cells and natural killer (NK) cell resistant tumor cell lines. The current study was undertaken to characterize biological agents which might modulate the induction of lymphokine (IL-2) activated killer (LAK) cells and to optimize culture conditions for LAK cell induction. Preliminary studies were undertaken to characterize optimal time and IL-2 concentration for induction of LAK cell activity. Subsequently, we demonstrated that: (a) LAK cell induction is inhibited at high (2.5 X 10(6)/ml) cell concentrations and this phenomenon is due to the presence of monocytes; (b) depletion of monocytes allows LAK cell induction at 5-10-fold higher cell concentrations without altering the extent or range of LAK-cell activity; (c) interleukin 1 enhances and alpha- and beta-interferons inhibit IL-2 induced proliferation, without altering LAK cell induction; and (d) gamma-interferon alters neither IL-2 induction of proliferation nor LAK cell activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2421884

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Simplified long term large scale production of highly active human LAK cells for therapy.

Authors:  P Wersäll; G Masucci; P Pihlstedt; H Wigzell; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

2.  Human lymphokine-activated killer (LAK) cells. I. Depletion of monocytes from peripheral blood mononuclear cells by L-phenylalanine methyl ester: an optimization of LAK cell generation at high cell density.

Authors:  K H Leung
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients.

Authors:  K Itoh; N R Pellis; C M Balch
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Indirect inhibition of generation of murine lymphokine-activated killer cell activity in splenocyte cultures by interferon-gamma.

Authors:  T Y Chao; H Ohnishi; T M Chu
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397

5.  Induction of activated natural killer cells from murine spleen cells primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432.

Authors:  H Yamaue; M Katsumi; K Tabuse; Y Tabuse; K Kuribayashi; T Nishihara; K Saito
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

6.  Evidence that interleukin-4 suppression of lymphokine-activated killer cell induction is mediated through monocytes.

Authors:  B Brooks; H Parry; J Lawry; R Rees
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

7.  Soluble factors produced by macrophages/monocytes inhibit lymphokine-activated killer activity in rat splenocyte cultures.

Authors:  P J Kuppen; A M Eggermont; R B Quak; A Marinelli; C J van de Velde; G J Fleuren
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

8.  Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity--IFN-gamma-induced suppressive activity.

Authors:  M Toledano; C Mathiot; J Michon; G Andreu; D Lando; M Brandely; W H Fridman
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

9.  Human lymphokine-activated killer (LAK) cells: III. Effect of L-phenylalanine methyl ester on LAK cell activation from human peripheral blood mononuclear cells: possible protease involvement of monocytes, natural killer cells and LAK cells.

Authors:  K H Leung
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

10.  Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients.

Authors:  K Yoneda; T Yamamoto; E Ueta; T Osaki
Journal:  J Clin Immunol       Date:  1992-07       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.